Indivior stock steadies after Supernus merger deal highlights $2.2 billion revenue goal
Published on 08/20/2026 at 16:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Indivior Pharmaceuticals, Inc. (ISIN GB00BYZ0C031) stock was quoted in the high-$38 to $39 range on August 20, 2026 as investors continued to assess the company’s planned combination with Supernus Pharmaceuticals and a projected combined revenue of $2.2 billion, according to recent biopharma sector reporting on the merger announced earlier this month.
Merger with Supernus sets a larger revenue base
A recent sector article on biopharma mergers reports that the business combination between Supernus Pharmaceuticals and Indivior Pharmaceuticals is expected to produce $2.2 billion in combined revenue, with management flagging likely overlaps in general and administrative functions following the deal announcement at the start of August 2026.
The same report emphasizes that workforce changes could follow the transaction as the combined company looks to streamline overheads, with the merger narrative framed as a move to build a larger specialty pharmaceutical platform around central nervous system and addiction-treatment products.
Indivior stock and market data context
On August 20, 2026, recent market-data snapshots showed Indivior Pharmaceuticals trading close to $39 per share on a US venue, with an indicative quote of $38.91 at 3:24 p.m. EDT and a small positive intraday move near 1.8 percent for that timestamp, while a separate screen of US stocks listed the shares at $39.04 with a modest daily decline of 0.99 percent from a prior reference price.
Across a short recent window, one CBOE-linked overview showed the stock at $39.06 at the August 19, 2026 close with a 0.94 percent drop on the day but a positive performance of 8.89 percent since the start of the year, underlining that despite minor day-to-day swings the year-to-date trajectory has been upward for shareholders.
A multi-asset trading page that lists Indivior among major US instruments also indicated a recent 52-week high around $42.81 and a 52-week low near $22.22, contextualizing the latest $39 area quote as being below the peak but well above the lower end of the past-year trading range, while assigning the company a market capitalization figure of $4.607 million on that particular list.
Latest fundamentals and earnings backdrop
Within the compact results available in this call, detailed current-quarter or fiscal-year numbers for Indivior’s standalone revenue, earnings per share and margins are not explicitly broken out, but the merger commentary’s $2.2 billion combined revenue figure nonetheless gives investors a directional sense of the scale management is targeting once the transaction closes.
Historically, Indivior has focused on addiction-treatment and psychiatry-related products, and the merger framework described in the biopharma sector article suggests that the combined enterprise will lean on established product franchises and pipeline assets to support that $2.2 billion revenue ambition, even if precise quarterly splits for Indivior alone are not spelled out in the limited data present here.
Representative product: addiction-treatment therapies
While the search results in this constrained call do not surface a specific branded product page for Indivior, the company’s long-standing positioning in addiction-treatment and related psychiatric therapies indicates that its commercial portfolio typically centers on medications designed to support patients with opioid dependency and similar conditions, with the merger expected to tie those assets more closely to a broader central nervous system-focused platform.
Indivior stock valuation snapshot
In the absence of a full current earnings table in these results, investors looking at Indivior stock around the $39 level on August 20, 2026 are primarily seeing a price that sits meaningfully above the lower bound of the stock’s 52-week range near $22.22 but still below the recent high of $42.81, suggesting scope for further upside if the combined company delivers on the $2.2 billion revenue target and manages the anticipated cost efficiencies from overlapping administrative functions.
Read more
Further details on Indivior’s investor relations materials and regulatory filings can be obtained via the company’s official investors page, which provides access to past financial reports, presentations and updates on strategic initiatives.
Company and stock facts
Company: Indivior Pharmaceuticals, Inc.
ISIN: GB00BYZ0C031
Ticker: INDV
Exchange: US venue (CBOE-linked listing)
Market cap: $4.607 million (as indicated on a recent US instruments overview as of August 20, 2026)
52-week range: $22.22 to $42.81 (per a multi-asset trading screen as of August 20, 2026)
Year-to-date performance: +8.89 percent (from a CBOE-linked market overview as of August 19, 2026)
